Vertex Pharmaceuticals
Jenny Inglefield is an experienced pharmaceutical executive currently serving as Vice President of Early Pipeline at Vertex Pharmaceuticals since October 2020. Previously, Inglefield held the title of Vice President for Rare Lysosomal Diseases at Takeda and also worked at Shire in various leadership roles, including Global Product Strategy Lead for Rare Genetic Diseases. With a strong background in market access strategy and global marketing, Inglefield's career began at GlaxoSmithKline and includes extensive experience in specialty pharmaceuticals. Inglefield holds a BSc in Medical Microbiology from The University of Edinburgh.
Vertex Pharmaceuticals
86 followers
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.